Funder
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Kontoghiorghes, G. J., Pattichis, K., Neocleous, K. & Kolnagou, A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr. Med. Chem. 11, 2161–2183 (2004).
2. Zhou, T., Ma, Y., Kong, X. & Hider, R. C. Design of iron chelators with therapeutic application. Dalton Trans. 41, 6371–6389 (2012).
3. Tanaka, T. et al. Apoptosis during iron chelator induced differentiation in F9 embryonal carcinoma cells. Cell Biol. Int. 23, 541–550 (1999).
4. Ido, Y. et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3. Cell Prolif. 32, 63–73 (1999).
5. Blatt, J., Taylor, S. R. & Kontoghiorghes, G. J. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res. 49, 2925–2927 (1989).
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献